Acrux announced the appointment of a new Chief Executive Officer and Managing Director, Mr. Michael Kotsanis. Michael is currently Chief Commercial Officer of Synthon Holding BV in the Netherlands. He has 25 years' experience in the global pharmaceutical industry, beginning his career with Boehringer Ingelheim before moving to F. H. Faulding (which was acquired by Mayne Group in 2001).

Michael has extensive pharmaceutical business development and commercialisation experience. He will join Acrux on November 3, 2014 and Current Executive Chairman Ross Dobinson will revert to the role of non-executive Chair from this date. The company also announced the resignation of its Chief Operating Officer, Dr. Clive Blower, effective August 15, 2014.